公司负责人（法定代表人）： 李守军 主管会计工作负责人： 李改变 会计机构负责人： 王彩霞 汇总表第 1页 | | | 制的其他企业 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 小计 | | | | 2,303.85 | 6,196.72 | | 6,168.14 | 2,332.43 | | | | | 瑞普(天津)生物药业有限公司 | 子公司 | 应收股利 | 5,000.00 | | | | 5,000.00 | 分红款 | 非经营性往来 | | | 瑞普高科(天津)生物技术有限公司 | 子公司 | 应收股利 | 4,000.00 | | | | 4,000.00 | 分红款 | 非经营性往来 | | | 广州市华南农大生物药品有限公司 | 子公司 | 应收股利 | | 7,025.00 | | 3,512.50 | 3,512.50 | 分红款 | 非经营性往来 | | | 湖北龙翔药业科技股份有限公司 | 子公司 | 应收股利 | 621.82 | | | | 621. ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-069 重要内容提示： 1、投资品种：委托银行、证券公司、资产管理公司等专业理财机构对公司 及子公司闲置自有资金进行投资和管理或者购买相关理财产品，包括银行理财产 品、资产管理公司资产管理计划、证券公司发行的各类产品等中、低风险产品。 2、投资额度：公司及子公司在任一时点使用闲置自有资金进行委托理财的 最高额度不超过人民币10亿元。 3、特别风险提示：公司进行委托理财可能面临的风险包括但不限于金融市 场波动风险、收益回报率不可预期风险、流动性风险、操作风险等。敬请投资者 注意投资风险。 瑞普生物股份有限公司（以下简称"公司"）于2025年8月22日召开第五届 董事会第二十六次会议及第五届监事会第二十二次会议，审议通过了《关于使用 闲置自有资金购买理财产品的议案》，为进一步提高公司资金使用效率，丰富投 资产品种类和渠道，同意公司在不影响正常经营的前提下，使用不超过人民币10 亿元的闲置自有资金购买风险可控、流动性好的中、低风险理财产品，单笔理财 产品期限最长不超过12个月；上述额度自董事会审议通过之日起12个月内有效， 在上述额度及期限内，资金可以 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-063 瑞普生物股份有限公司 2025 年第四次临时股东大会决议公告 二、议案审议表决情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 瑞普生物股份有限公司（以下简称"公司"）2025年8月9日以董事会公告方式 向全体股东发出召开2025年第四次临时股东大会的通知。（公告编号：2025-061）。 本次股东大会采取现场投票、网络投票相结合的方式召开。其中现场会议于2025 年8月25日下午14:30在公司会议室召开，会议由董事长李守军先生主持；通过深圳 证券交易所系统进行网络投票的时间为2025年8月25日09:15-09:25，09:30-11:30， 13:00-15:00；通过深圳证券交易所互联网系统投票的具体时间为2025年8月25日 09:15-15:00期间的任意时间。 公司总股本464,754,706股，扣除公司股份回购专户的股份数后，公司有表决权 ...

本次股东大会采取现场表决和网络投票相结合的表决方式。本次股东大会现 场会议于 2025 年 8 月 25 日 14:30 在天津市自贸试验区（空港经济区）东九道 1 号公司会议室如期举行。网络投票时间为：（1）通过深圳证券交易所交易系统 进行网络投票的具体时间为：2025 年 8 月 25 日 9:15-9:25，9:30-11:30 和 13:00-15:00；（2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 25 日 9:15-15:00 期间的任意时间。 中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于瑞普生物股份有限公司 2025 年第 ...

Market Overview - On August 25, the animal health sector rose by 1.47%, led by Shenlian Biological, while the Shanghai Composite Index closed at 3883.56, up 1.51%, and the Shenzhen Component Index closed at 12441.07, up 2.26% [1]. Stock Performance - Shenlian Biological (688088) closed at 14.50, with a significant increase of 13.81% and a trading volume of 521,000 shares, amounting to 723 million yuan [1]. - Other notable stocks included: - KQ Biological (688526) at 18.10, up 2.67% [1]. - Dayu Biological (871970) at 10.25, up 1.18% [1]. - Huisheng Biological (300871) at 23.75, up 0.93% [1]. - Ruip Biological (300119) at 23.48, up 0.86% [1]. - Jinhai Biological (002688) at 7.31, up 0.55% [1]. Capital Flow - The animal health sector experienced a net outflow of 40.13 million yuan from institutional investors, while retail investors saw a net outflow of 60.97 million yuan. Conversely, speculative funds had a net inflow of 101 million yuan [2]. Individual Stock Capital Flow - Shenlian Biological had a net inflow of 35.39 million yuan from institutional investors, while retail investors faced a net outflow of 74.83 million yuan [3]. - Other stocks with notable capital flows included: - Pulaike (603566) with a net inflow of 3.28 million yuan from institutional investors and a net outflow of 9.68 million yuan from retail investors [3]. - Huisheng Biological (300871) had a net inflow of 2.55 million yuan from institutional investors but a net outflow of 13.77 million yuan from retail investors [3].

Investment Rating - The report maintains a "Buy" rating for the agriculture, forestry, animal husbandry, and fishery sector [4] Core Viewpoints - The report indicates that the destocking phase for live pigs is nearing its end, with a focus on the effects of a new round of pork reserves [1] - The report highlights a recent decline in pork prices, with the average price for live pigs at 13.75 yuan/kg, down 0.07% week-on-week, and a significant drop in the price of piglets by 3.78% to 27.78 yuan/kg [1][22] - The report notes an increase in the average weight of slaughtered pigs, which is expected to stabilize prices as the government resumes pork reserves to boost market sentiment [1][22] Summary by Sections 1. Market Overview - The agriculture, forestry, animal husbandry, and fishery sector underperformed compared to the broader market, with the sector index rising by 3.72% while the Shanghai Composite Index rose by 3.49% [13] - The report provides a detailed performance breakdown of sub-sectors, with livestock farming showing a 4.31% increase [13] 2. Key Data Tracking 2.1 Live Pigs - The average weight of slaughtered pigs is reported at 127.98 kg, showing a slight increase of 0.16 kg week-on-week [22] - The national frozen meat storage capacity rate is at 14.77%, up 0.1 percentage points [22] 2.2 White Feather Broilers - The price of white feather broilers increased to 7.33 yuan/kg, up 1.81% week-on-week, while chick prices remained stable at 3.58 yuan each [31] 2.3 Yellow Feather Broilers - The price of medium-speed chickens rose to 6.34 yuan/jin, reflecting a 4.97% increase, driven by rising demand post-typhoon [40] 2.4 Feed Sector - The report notes a decline in the prices of corn, wheat, and soybean meal, with corn averaging 2373.53 yuan/ton, down 0.86% week-on-week [2][45] 2.5 Major Agricultural Products - The price of natural rubber fell to 15640 yuan/ton, down 0.89% week-on-week, with inventory levels decreasing slightly [60] 3. Investment Recommendations - The report recommends focusing on the pig farming sector, suggesting that the long-term profitability cycle is beginning to improve, with specific companies highlighted for investment: Muyuan Foods, Wens Foodstuff Group, Juxing Agriculture, and Shennong Group [3] - It also suggests monitoring the feed and animal health sectors, particularly companies like Haida Group and Ruipu Biological, as demand is expected to rise [3] - In the planting chain, the report identifies investment opportunities in companies such as Suqian Agricultural Development and Beidahuang Group due to favorable grain price trends [3]

Group 1 - The core stock price of Reap Bio as of August 22, 2025, is 23.28 yuan, down 0.51% from the previous trading day, with a trading volume of 96,700 hands and a transaction amount of 224 million yuan [1] - Reap Bio's main business includes veterinary medicine and pet healthcare, with product lines such as animal vaccines, chemical drugs, and feed additives, and the company is actively expanding into the pet healthcare market [1] - The company forecasts a net profit attributable to shareholders for the first half of 2025 to be between 244 million yuan and 277 million yuan, representing a year-on-year growth of 50% to 70%, driven by rapid expansion in the pet healthcare sector and overseas market development [1] Group 2 - On the funding flow side, Reap Bio experienced a net outflow of 12.61 million yuan in main funds on the day, while there was a net inflow of 1.25 million yuan in the past five days [1]

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]

Company Overview - Reap Bio is located in Tianjin Free Trade Zone and was established on August 2, 2001, with its listing date on September 17, 2010 [1] - The company specializes in veterinary biological products (animal vaccines) and chemical pharmaceuticals [1] Stock Performance - As of August 22, Reap Bio's stock price decreased by 2.01%, trading at 22.93 CNY per share, with a total market capitalization of 10.657 billion CNY [1] - Year-to-date, the stock price has increased by 26.85%, with a 0.66% rise over the last five trading days, a 4.61% increase over the last 20 days, and a 7.02% decline over the last 60 days [1] Financial Performance - For the period from January to March 2025, Reap Bio reported a revenue of 822 million CNY, representing a year-on-year growth of 54.09% [2] - The company has distributed a total of 1.371 billion CNY in dividends since its A-share listing, with 462 million CNY distributed over the last three years [2] Shareholder Information - As of August 8, the number of shareholders for Reap Bio was 27,000, with an average of 12,406 circulating shares per shareholder [2] - As of March 31, 2025, the fifth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 6.3889 million shares, an increase of 696,900 shares from the previous period [2] Market Activity - On August 22, the net outflow of main funds was 7.9021 million CNY, with large orders accounting for 15.94% of purchases and 21% of sales [1]